Audited Financial Results for the Quarter and Year ended on 31st March 2026 along with Auditors Report
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novyra Pharmachem Limited (formerly Bansisons Tea Industries Ltd) reported audited results for FY 2025-26 with total revenue of Rs. 16.75 lakh, up from Rs. 4.80 lakh in the previous year, representing revenue growth of approximately 249%. However, the company reported a massive net loss of Rs. 537.38 lakh compared to a loss of Rs. 6.36 lakh in FY 2024-25. The Tea Estate segment contributed Rs. 8.94 lakh in revenue but recorded a loss of Rs. 449.39 lakh, indicating significant operational issues in this segment. Cash flow from operations was negative at Rs. 372.31 lakh. The statutory auditor issued an unmodified (clean) opinion on the financial results.
Despite revenue growth, the company is experiencing severe financial stress with exponentially increasing losses and negative operating cash flows. The name change from tea to pharma suggests a strategic shift, but the Tea Estate segment continues to drag down performance. Shareholders should monitor the company's ability to fund operations given negative cash flows and mounting losses.